Page 147 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 147
PET improves DLBCL response predictors Supplemental Table 4. Uni- and multivariable Cox Proportional Hazard analyses of ∆SUVmax analysis-
group for 2-year PFS (n=367).
Age (≤60 vs >60)
aaIPI (low/low-intermediate vs high-intermediate/high)
B symptoms (no vs yes)
∆SUVmax (>70% vs ≤70%)
Gender (male vs female)
Treatment arm (R-CHOP14 vs RR-CHOP14
* Statistically significant difference
2-year PFS
1·60 (0·95-2·69) 3·16 (1·80-5·55)
1·67 (1·07-2·61) 4·80 (2·88-8·00) 1·25 (0·80-1·96) 0·99 (0·63-1·54)
0·075 <0·0001*
0·025* <0·0001* 0·335 0·957
3·27 (1·86-5·75) 5·01 (3·00-8·36)
<0·0001* <0·0001*
Univariate P-value Multivariable P-value HR (95%CI) HR (95%CI)
Abbreviations: 95%CI= 95% confidence interval; aaIPI= age-adjusted international prognostic index; ∆SUVmax= reduction of maximum standardized uptake value between baseline and interim 18F-FDG PET(/CT); HR= Hazard Ratio; LDH= lactate dehydrogenase; PFS= progression-free survival; WHO= world health organization.
145
6a
